

SANTIAGO BREAST CANCER

MARCH 30, 31 and APRIL 1st; 2020

Monday 30, am

08:15 – 08:45	Registration	
	Breast cancer patient quality of life	
08:45 – 09:00	Welcome Soledad Torres, MD – José Miguel Reyes, MD – Hernando Paredes, MD	
09:00 – 09:30	Dealing with vaginal atrophy due to chemotherapy and endocrine therapy. Marco A. Levancini, MD	
09:30 – 09:50	Self-image after breast cancer surgery and reconstruction. Claudia Acevedo, MD.	
09:50 – 10:10	Management of lifestyle risk factors for breast cancer. -Body mass index -Physical activity Maria J. Escaffi, MD	
10:10 – 10:30	Bone density and breast cancer treatment. Sergio Brantes, MD	
10:30 - 11:00	Coffee Break	
11: 00 - 11:30	Plenary Conference: Lymphoedema after breast cancer treatment: new approaches and risks factors. Alphonse Taghian, MD	
11:30 - 11:50	Surgical management of lymphoedema. Nicolás Pereira, MD	
11:50 - 12:20	Plenary Conference: Breast cancer screening. New advances. Christopher Comstock, MD	
12:30 - 14:00	AstraZeneca Symposium	12:30 – 13:30 Salón Canelo Patient Advocacy Activity What do we have after treatment? Breast cancer survivors talk about different topics to deal with after treatment. Drs. Rojas, Escafi, Bravo, Reyes

Monday 30, pm

Hereditary breast cancer management

14:00 -14:20	Incorporating low-risk alleles for improve accuracy in breast cancer risk. Banu Arun, MD	
14:20 - 14:40	Recommendation after a moderate-risk gene mutation finding. Genetic modifiers of BRCA1/2: are we ready for polygenic risk score in the BRCA carrier clinic? Joan Brunet, MD	
14:40 - 15:00	Telemedicine and other distance tools in hospitals and community hospitals to improve genetic testing in low-income populations Lina Nuñez, MD	
15:00 - 15:20	Tumor testing versus germline testing: When the genetic germline study is indicated after the detection of a pathogenic tumor variant. Joan Brunet, MD	
15:20 - 15:50	Screening and follow-up in high-risk population Christopher Comstock, MD	
15:50 - 16:10	Coffee break	
16:10 – 16:20	Managing breast cancer risk after ovarian cancer in a BRCA mutation carriers. Joan Brunet, MD	
16:20 – 16:50	Breast cancer pathology, treatment and outcome in ATM, BRCA1, BRCA 2, CHECK 2 and PALB2 mutation carriers. Banu Arun, MD	

16:50 – 17:10	Legal, ethical and confidential aspects of genetic testing in Latin America. Lina Nuñez, MD
17:10 – 17:30	Genetic testing for all patients with breast cancer? Should we follow the ASBrS guidelines? Banu Arun, MD
17:30 – 17:50	Risk assessment models what is known and what is new (BOADICEA, Tyrer-Cuzik) Juan M. Donaire, MD
17:50 – 18:05	Round table. Discussion
16:10 – 17:30	AstraZeneca Work - shop (by invitation only)

Tuesday 31, am	
08:15 - 08:30	Registration
DCIS mini symposium	
08:30 - 08:50	Pathology as an instrument for selective management of DCIS. Vicente Peg, MD
08:50 - 09:10	Advances in the management of DCIS. Alfredo Barros, MD.
09:10 - 09:30	Could we omit radiotherapy in patients with DCIS? Alphonse Taghian, MD
09:30 - 10:00	Best submitted abstracts
10:00 - 10:10	Invited discussant
10:10 - 10:30	Coffee break
10:30 - 10:55	Plenary conference: Is it possible to perform conservative surgery in patients with multifocal/multicentric synchronous ipsilateral cancers? Alfredo Barros, MD
Endocrine Positive Disease	
10:55 - 11:15	Role of pathology in planning endocrine therapy. Vicente Peg, MD
11:15 - 11:35	Chemotherapy or endocrine neoadjuvant therapy for luminal breast cancer. Mothaffar Rimawi, MD
11:35 - 11:55	Novel drugs for neoadjuvant endocrine therapy. Are ready for clinical use? Aleix Prat, MD
12:00 - 13:00	Early Breast cancer clinical cases discussion. César Sanchez, MD
13:00 - 14:30	Industry Symposium with lunch. MSD
Tuesday 31, pm	
14:30 - 14:50	Molecular platforms for adjuvant cancer treatment. Which patients really benefit from these tests? Vicente Peg, MD
14:50 - 15:10	Which agent and duration of adjuvant endocrine therapy. Mothaffar Rimawi, MD
15:10 – 15:30	New drugs beyond CDK4/6 inhibitors for the treatment of metastatic breast cancer. Aleix Prat, MD
15:30 – 15:50	Cyclin inhibitors for luminal metastatic breast cancer. Mothaffar Rimawi, MD.
15:50–16:10	Treating metastatic luminal breast cancer patient: Is chemotherapy still an option? Mafalda Oliveira, MD
16:10 – 16:30	Coffee Break
Triple Negative Disease	

16:30—16:50	Something new in pathology of triple negative disease? Patients selection for check-points inhibitors. Vicente Peg, MD	
16:50—17:10	Preoperative medical treatment for triple negative disease: advances in the last two years? Mafalda Oliveira, MD	
17:10—17:40	Best submitted abstracts.	
17:40—17:50	Invited discussant	
17:50—18:10	Determining response after neoadjuvant treatment: role of MRI and core biopsy. Christopher Comstock, MD	18:00 – 19:00 Salón Canelo Workshop: Gemonics Platforms: From clinical validation to clinical practice. Fernando Petracci, MD
18:10—18:30	Question and Answer	

Wednesday 01, am

08:15 - 08:30	Registration	
08:30 - 08:50	Triple negative patient with residual disease after neoadjuvant treatment: only capecitabine or something new? Jennifer K. Litton, MD	
08:50 - 09:10	What is new for the management of metastatic triple negative disease? Mafalda Oliveira, MD	
09:10 - 09:30	Which patients benefit from immune therapy with check-point inhibitors? When and for whom are they indicated? Ana Lluch, MD	
09:30 - 09:50	PARP inhibitors and beyond. Jeniffer Litton, MD	
09:50 - 10:20	Best submitted abstract	
10:20 - 10:30	Invited discussant	
10:30 - 10:50	Coffee break	
HER-2 positive disease		
10:50 - 11:10	Neoadjuvant treatment for HER – 2 positive disease. Update of the data. Could we avoid chemotherapy? Aleix Prat, MD	
11:10 - 11:30	Management of the patient HER-2 positive disease with residual disease after neoadjuvant treatment: With hormonal receptors positive and with hormonal receptor negative. Ana Lluch, MD	
11:30 - 11:50	Adjuvant treatment for HER-2 positive disease. How many and which agents? Mothaffar Rimawi, MD	
11:50 - 12:10	Advanced or metastatic HER-2 positive disease: current treatment and new advances. Ana Lluch, MD.	
12:10 - 13:10	Advanced breast cancer clinical cases discussion. Jose M Reyes, MD	
13:10 - 14:30	Industry symposium	
Wednesday 01, pm		
14:30 -15:15	Debate: Do we always have to dissect the axilla after preoperative medical treatment with previous clinically positive axilla	
14:30 -14:35	Clinical case presentation	
14:35 -14:45	PRO	
14:45 - 14:55	CONS	
14:55 - 15:15	Plenary discussion	
15:15 - 15:35	Radiotherapy of the axilla after adjuvant and neoadjuvant treatment.	

	Alphonse Taghian, MD.
15:35 - 15:45	Best submitted abstract award. Reyes, Paredes, Torres y Pfizer representative.
15:45 -16:15	Coffee break
16:15-16:35	Reconstruction after conservative surgery. Edward Chang, MD
16:35-16:55	Partial breast irradiation. Alphonse Taghian, MD
16:55-17:15	Prothesis associated lymphoma: Diagnosis and management. Edward Chang, MD
17:15-17:25	Question and Answer
17:25	Adjourn